Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents
Petr O Ilyinskii, Christopher Roy, Alicia Michaud, Gina Rizzo, Teresa Capela, Sheldon S Leung, Takashi Kei Kishimoto · 2023
Read Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents by Petr O Ilyinskii, Christopher Roy, Alicia Michaud, Gina Rizzo, Teresa Capela, Sheldon S Leung, Takashi Kei Kishimoto (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10673641.txt.
Description
Tolerogenic ImmTOR nanoparticles encapsulating rapamycin have been demonstrated to mitigate immunogenicity of adeno-associated virus (AAV) gene therapy vectors, enhance levels of transgene expression, and enable redosing of AAV at moderate vector doses of 2 to 5E12 vg/kg. However, recent clinical trials have often pushed AAV vector doses 10-fold to 50-fold higher, with serious adverse events observed at the upper range.
Catalog record
| CREATOR | Petr O Ilyinskii, Christopher Roy, Alicia Michaud, Gina Rizzo, Teresa Capela, Sheldon S Leung, Takashi Kei Kishimoto |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |